#	Pagina
attuale pagina	/open-h2020/projects/225004/index.html
-1	/open-h2020/projects/209471/index.html
-2	/open-h2020/projects/216286/index.html
-3	/open-h2020/projects/193909/deliverables.html
-4	/open-h2020/per-topic/virtually/list/index.html
-5	/open-h2020/projects/209259/index.html
-6	/open-h2020/projects/218255/index.html
-7	/open-h2020/projects/220696/index.html
-8	/open-h2020/per-topic/compute/list/index.html
-9	/open-h2020/projects/217767/deliverables.html
-10	/open-h2020/per-topic/developmental/list/index.html

Opendata, web and dolomites

StopAddict SIGNED

The game changer drug to cure alcohol use disorders

Total Cost €

EC-Contrib. €

Partnership

Views

StopAddict project word cloud

Explore the words cloud of the StopAddict project. It provides you a very rough idea of what is the project "StopAddict" about.

trial treatments clinical save commercialisation generating unsuccessful disability decreasing kt alcoholism pharma 283 110 alcohol characterised huge disorders burden mechanism 2018 life successful stopaddict continuous lives patient poor kinnov triple 2025 context action mise billion expenses actions regulatory drug people recovery 10 uncontrolled neuropsychopharmacology therapeutics agency companies disease intensive class fto 2009 efficacy cumulative revolutionary implicated persons newly seeking situation 132 man award 2027 adjusted updated society accepted 117m ip achievement worldwide addiction first patients 70 discovered create social aud suffer smei2 400 direct treatment consumption granted million french communities licensing college deals damaging leads indirect revenues leader therapies dead jobs families

Project "StopAddict" data sheet

The following table provides information about the project.

Coordinator	KINNOV THERAPEUTICS Organization address address: 3 ALLEE DU TITANE city: Orleans postcode: 45100 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Total cost	3˙432˙400 €
EC max contribution	2˙402˙680 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-2
Funding Scheme	SME-2
Starting year	2019
Duration (year-month-day)	from 2019-10-01 to 2021-09-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	KINNOV THERAPEUTICS KINNOV THERAPEUTICS Organization address address: 3 ALLEE DU TITANE city: Orleans postcode: 45100 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (Orleans)	coordinator	2˙402˙680.00

Map

Project objective

Alcohol use disorders (AUD) is a disease characterised by uncontrolled alcohol consumption. 283 million persons worldwide suffer from alcohol mise use which cause more than 3 million dead and 132.6 million disability-adjusted life years. Alcoholism has also huge damaging effects on families, communities and the overall society. Current drug therapies against AUD are unsuccessful due to poor efficacy and strong side effects. That situation leads to low patient recovery and only 10% of AUD people seeking for treatment. In this context, Kinnov-Therapeutics has developed a new revolutionary first-in-class drug allowing patients to control their alcohol consumption. KT-110 drug will highly impact the European burden of AUD by decreasing alcohol consumption on AUD patients by 70% leading to triple the number of AUD people seeking for treatments and save more than 5 million lives per year and several billion of social cost expenses. The efficacy of KT-110 is related to its action on a newly discovered pathway highly implicated in alcohol addiction. This major understanding of AUD addiction mechanism was granted the European college of neuropsychopharmacology Neuropsychopharmacology Award in 2009. After 20 years of intensive research and pre-clinical development, KT-110 has been accepted by the french regulatory agency for its first-in man phase II clinical trial by the end of 2018. This will be the main achievement of SMEi2 project. Moreover, all necessary actions for successful commercialisation to pharma companies (licensing deals) as well as continuous and updated IP and FTO issues are planned to be implemented during the SMEi2. Through StopAddict project KT-110 will become the next leader of AUD treatments by generating €117m of cumulative revenues between 2025-2027. Our project will also allow to create more than 400 direct and indirect European jobs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STOPADDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STOPADDICT" are provided by the European Opendata Portal: CORDIS opendata.